Christina Gentry, DVM, DACVM, discusses concurrent diseases and skin emergencies, in a dvm360 interview.

If you're an existing patient of this provider, please use your U of U Health (MyChart) account to schedule your appointment. If you're having trouble signing in, need guidance on using U of U Health ...

InflaRx ( (IFRX)) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

SPOKANE, Wash. — A family is pleading for help to save the life of Ryan Becker, who is fighting an extremely rare and devastating illness known as Pyoderma Gangrenosum, a condition described by ...

SPOKANE, Wash. — A Spokane father is facing a devastating choice between financial ruin and his life as he battles an extremely rare disease that requires tens of thousands in monthly medication to ...

InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its Phase 3 trial for vilobelimab in pyoderma gangrenosum/PG would be ...

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...